Addressing Dementia Via Agitation-Centered Evaluation

NCT ID: NCT03226522

Last Updated: 2023-09-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

366 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-13

Study Completion Date

2020-04-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Agitation in Patients With Dementia of the Alzheimer's Type Alzheimer Disease Agitation,Psychomotor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AXS-05

AXS-05 tablets taken by mouth for 5 weeks.

Group Type EXPERIMENTAL

AXS-05

Intervention Type DRUG

AXS-05

Bupropion

Bupropion tablets taken by mouth for 5 weeks.

Group Type ACTIVE_COMPARATOR

Bupropion

Intervention Type DRUG

Bupropion

Placebo

Placebo tablets taken by mouth for 5 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AXS-05

AXS-05

Intervention Type DRUG

Bupropion

Bupropion

Intervention Type DRUG

Placebo

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
* Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.

Exclusion Criteria

* Patient has dementia predominantly of non-Alzheimer's type.
* Unable to comply with study procedures.
* Medically inappropriate for study participation in the opinion of the investigator.
Minimum Eligible Age

65 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Axsome Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Axsome Study Site

Gilbert, Arizona, United States

Site Status

Axsome Study Site

Phoenix, Arizona, United States

Site Status

Axsome study site

Scottsdale, Arizona, United States

Site Status

Axsome study site

Scottsdale, Arizona, United States

Site Status

Axsome Study Site

Tucson, Arizona, United States

Site Status

Axsome Study Site

Little Rock, Arkansas, United States

Site Status

Axsome study site

Canoga Park, California, United States

Site Status

Axsome study site

Costa Mesa, California, United States

Site Status

Axsome study site

Fresno, California, United States

Site Status

Axsome study site

Long Beach, California, United States

Site Status

Axsome study site

Long Beach, California, United States

Site Status

Axsome Study Site

Los Alamitos, California, United States

Site Status

Axsome study site

Riverside, California, United States

Site Status

Axsome study site

Sacramento, California, United States

Site Status

Axsome study site

Santa Ana, California, United States

Site Status

Axsome Study Site

Santa Clarita, California, United States

Site Status

Axsome study site

Sherman Oaks, California, United States

Site Status

Axsome study site

Simi Valley, California, United States

Site Status

Axsome study site

Temecula, California, United States

Site Status

Axsome study site

Ventura, California, United States

Site Status

Axsome Study Site

Colorado Springs, Colorado, United States

Site Status

Axsome study site

Cromwell, Connecticut, United States

Site Status

Axsome study site

New London, Connecticut, United States

Site Status

Axsome Study Site

Apopka, Florida, United States

Site Status

Axsome study site

Boca Raton, Florida, United States

Site Status

Axsome study site

Boynton Beach, Florida, United States

Site Status

Axsome Study Site

Coconut Creek, Florida, United States

Site Status

Axsome Study Site

Greenacres City, Florida, United States

Site Status

Axsome study site

Hallandale, Florida, United States

Site Status

Axsome study site

Hialeah, Florida, United States

Site Status

Axsome Study Site

Lake City, Florida, United States

Site Status

Axsome study site

Miami, Florida, United States

Site Status

Axsome study site

Miami, Florida, United States

Site Status

Axsome Study Site

Orlando, Florida, United States

Site Status

Axsome study site

Pensacola, Florida, United States

Site Status

Axsome Study Site

Port Orange, Florida, United States

Site Status

Axsome study site

Spring Hill, Florida, United States

Site Status

Axsome study site

Tampa, Florida, United States

Site Status

Axsome study site

Tampa, Florida, United States

Site Status

Axsome study site

Atlanta, Georgia, United States

Site Status

Axsome study site

Decatur, Georgia, United States

Site Status

Axsome Study Site

Honolulu, Hawaii, United States

Site Status

Axsome study site

Boise, Idaho, United States

Site Status

Axsome Study Site

Flossmoor, Illinois, United States

Site Status

Axsome study site

Avon, Indiana, United States

Site Status

Axsome Study Site

Overland Park, Kansas, United States

Site Status

Axsome Study Site

Topeka, Kansas, United States

Site Status

Axsome study site

Baton Rouge, Louisiana, United States

Site Status

Axsome Study Site

Lake Charles, Louisiana, United States

Site Status

Axsome Study Site

Hattiesburg, Mississippi, United States

Site Status

Axsome study site

Chesterfield, Missouri, United States

Site Status

Axsome Study Site

St Louis, Missouri, United States

Site Status

Axsome study site

Las Vegas, Nevada, United States

Site Status

Axsome Study Site

Las Vegas, Nevada, United States

Site Status

Axsome Study Site

Princeton, New Jersey, United States

Site Status

Axsome study site

Toms River, New Jersey, United States

Site Status

Axsome Study Site

Albany, New York, United States

Site Status

Axsome study site

Brooklyn, New York, United States

Site Status

Axsome study site

New York, New York, United States

Site Status

Axsome study site

New York, New York, United States

Site Status

Axsome study site

Staten Island, New York, United States

Site Status

Axsome Study Site

Charlotte, North Carolina, United States

Site Status

Axsome study site

Charlotte, North Carolina, United States

Site Status

Axsome Study Site

Winston-Salem, North Carolina, United States

Site Status

Axsome study site

Cincinnati, Ohio, United States

Site Status

Axsome Study Site

Dayton, Ohio, United States

Site Status

Axsome study site

Shaker Heights, Ohio, United States

Site Status

Axsome Study Site

Oklahoma City, Oklahoma, United States

Site Status

Axsome study site

DeSoto, Texas, United States

Site Status

Axsome Study Site

McKinney, Texas, United States

Site Status

Axsome study site

Wichita Falls, Texas, United States

Site Status

Axsome study site

Orem, Utah, United States

Site Status

Axsome Study Site

Charlottesville, Virginia, United States

Site Status

Axsome Study Site

Richmond, Virginia, United States

Site Status

Axsome study site

Bellevue, Washington, United States

Site Status

Axsome Study Site

Everett, Washington, United States

Site Status

Axsome study site

Spokane, Washington, United States

Site Status

Axsome study site

Caulfield, Melbourne, Victoria, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

http://www.axsome.com

Axsome Therapeutics Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AXS-05-AD-301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Memantine for Agitation in Dementia
NCT00371059 COMPLETED PHASE4